Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis

Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

(2009) Dimitrios Pectasides et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2008) R. Dummer et al.   ANNALS OF ONCOLOGY

Adjuvant low-dose interferon  2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

(2008) C. Garbe et al.   ANNALS OF ONCOLOGY

Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals

(2008) Simone Mathoulin-Pelissier et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

(2008) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy of melanoma with interferon: lessons of the past decade

(2008) Paolo A Ascierto et al.   Journal of Translational Medicine

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET

Management of Melanoma: A European Perspective

(2008) Alexander M.M. Eggermont et al.   Surgical Oncology Clinics of North America